Biofrontera Reports Record 2025 Revenue of $41.7 Million and Best-Ever Q4 at $17.1 Million

Overview

• The company said full-year revenue rose about 12% from 2024 to $41.7 million.
• Fourth-quarter revenue reached $17.1 million, up approximately 36% year over year and the highest in company history.
• Executives cited stronger commercial execution and growing Ameluz PDT use across dermatology practices as key drivers.
• Management noted an amendment to its contractual relationship with former parent Biofrontera AG and indicated details would be addressed on the call.
• The presentation included Safe Harbor cautions and references to non-GAAP metrics such as adjusted EBITDA, with GAAP reconciliations available in the press release and on the investor website.